We retrospectively studied 46 eyes of consecutive 45 patients (23 men, 22 women) with BRVO between April and December 2013 at one academic institution. The institutional review board approved the study and all patients provided informed consent. The inclusion criteria included eyes with BRVO for which SS-OCT (DRI OCT-1; Topcon Corp., Tokyo, Japan) and high-speed FA with a confocal laser scanning system (HRA-2; Heidelberg Engineering, Heidelberg, Germany) obtained images of sufficient quality and a duration of symptoms less than 24 months. Branch retinal vein occlusion was diagnosed based on a comprehensive ophthalmologic examination that included indirect ophthalmoscopy, slit-lamp biomicroscopy with a contact lens, FA, and SD-OCT (Cirrus HD-OCT; Carl Zeiss Meditec; Jena, Thuringia, Germany). The best-corrected visual acuity (BCVA) using a Landolt chart and IOP were measured at every visit. Eyes were excluded if they had undergone a previous vitrectomy or laser photocoagulation within the arcade or received an intravitreal injection of an anti-VEGF agent within 3 months before SS-OCT and FA were performed. Eyes with a coexisting ocular disease (i.e., epiretinal membrane, glaucoma, or proliferative diabetic retinopathy) were not recruited for this study.